Ollin Biosciences announced positive topline results from its randomized, head-to-head phase 1b JADE clinical study evaluating OLN324, a next-generation VEGF/Ang2 bispecific antibody, versus faricimab (Vabysmo; Genentech). The study enrolled more than 160 patients with diabetic macular edema (DME) or wet age-related macular degeneration (AMD) across sites in the United States.

According to Ollin, the results demonstrated that OLN324 achieved faster and greater anatomic improvements compared with faricimab in patients with DME, while delivering comparable outcomes in wet AMD. According to the company, OLN324’s differentiated profile is driven by its up to 60-fold higher anti-Ang2 potency, smaller protein format, and higher molar dose—features that may support its potential as a first-line standard of care.

In patients with DME, OLN324 showed superior retinal drying as measured by optical coherence tomography (OCT). Patients treated with OLN324 4 mg experienced mean reductions in central subfield thickness (CST) that were approximately 75% greater than faricimab at Week 1 (–79 µm vs. –45 µm) and about 50% greater at Week 12 (–180 µm vs. –121 µm). Nearly 90% of patients treated with OLN324 4 mg achieved absence of DME at Week 12, defined as CST below 325 µm, compared with 57% of patients treated with faricimab, according to Ollin.

In wet AMD, all treatment groups achieved equivalent anatomic outcomes, with rapid improvements in mean CST observed as early as Week 1 and sustained through Week 12. Across both DME and wet AMD populations, patients experienced rapid and sustained improvements in vision, as measured by best-corrected visual acuity (BCVA), with numerically greater gains at Week 12 observed in OLN324-treated patients compared with faricimab.

“OLN324 is the first and only therapy to demonstrate superior anatomic efficacy compared to the market leader, faricimab, in a head-to-head, randomized clinical trial,” said Jason Ehrlich, MD, PhD, co-founder and CEO of Ollin Biosciences. “These data validate that a higher potency, higher molar dose, smaller format VEGF/Ang2 bispecific can more fully realize the therapeutic potential of dual VEGF and Ang2 inhibition. By achieving faster and greater retinal drying in DME, OLN324 has the potential to become the new standard of care in the approximately $15 billion worldwide retinal therapeutics market.”

The JADE study demonstrated a favorable safety profile for OLN324. No cases of intraocular inflammation (IOI) were observed in patients treated with OLN324 at either dose level, while one case of IOI occurred in a faricimab-treated patient. No cases of retinal vasculitis or occlusive retinal vasculitis were reported, according to Ollin.

Based on these results, Ollin said it plans to engage with regulatory authorities and advance OLN324 into global phase 3 studies in both DME and wet AMD. The company will discuss the JADE study findings and broader pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. Full study results are scheduled to be presented for the first time at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026.